Inflammation Research

, Volume 62, Issue 10, pp 919–927 | Cite as

Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort

  • Darcy S. Majka
  • Kiang Liu
  • Richard M. Pope
  • Elizabeth W. Karlson
  • Thanh-Huyen T. Vu
  • Marius Teodorescu
  • Rowland W. Chang
Original Research Paper


Objective and design

Antiphospholipid antibodies (APA) have been associated with clinical cardiovascular disease, but it remains unclear whether APA are associated with sub-clinical atherosclerosis. This study examined the relationship between APA and sub-clinical atherosclerosis, measured as coronary artery calcification (CAC), in participants from the prospective Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Subjects and method

2,203 black and white participants with sera available from the CARDIA year 7 examination and CAC measured by computed tomography at years 15 or 20 were selected.


Anti-β2-glycoprotein I (anti-β2-GPI) immunoglobulin (Ig) M, IgG, and IgA were positive in 7.0, 1.4, and 1.8 % of participants, respectively; anti-cardiolipin (aCL) IgM and IgG were positive in 1.5 and 1.0 %, respectively. 9.5 % of participants had CAC score >0 at year 15. Anti-β2-GPI IgM, IgG, IgA, and aCL IgG positivity were associated with CAC >0 at year 15 after adjustment for traditional cardiovascular risk factors; [odds ratios (95 % confidence intervals) were 1.7 (1.0, 3.1), 6.4 (2.4, 16.8), 5.6 (2.3, 13.2), and 5.1 (1.4, 18.6), respectively]. Anti-β2-GPI IgG was associated with year 20 CAC >0, and anti-β2-GPI IgA and aCL IgG were marginally associated.


These findings indicate that APA positivity during young adulthood is a risk factor for subsequent sub-clinical atherosclerosis and might play a role in the pathogenesis of atherosclerosis.


Antiphospholipid antibodies Cardiovascular disease Coronary atherosclerosis Coronary artery calcification EBCT MDCT 


  1. 1.
    Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104(15):1863–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000;59(5):321–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46(4):862–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Grainger DJ, Bethell HW. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis. 2002;61(2):110–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ, Harats D, George J, Levy Y, Peter JB, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology. 2001;95(1):20–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007;6(6):379–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Liang KP, Kremers HM, Crowson CS, Snyder MR, Therneau TM, Roger VL, Gabriel SE. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36(11):2462–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Shoenfeld Y, Sherer Y, George J, Harats D. Autoantibodies associated with atherosclerosis. Ann Med. 2000;32(Suppl 1):37–40.PubMedGoogle Scholar
  9. 9.
    Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32(8):1701–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kobayashi K, Lopez LR, Matsuura E. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Ann N Y Acad Sci. 2007;1108:489–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107(3):569–73.PubMedCrossRefGoogle Scholar
  12. 12.
    George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000;102(15):1822–7.CrossRefGoogle Scholar
  13. 13.
    George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998;98(11):1108–15.CrossRefGoogle Scholar
  14. 14.
    Matsuura E, Lopez LR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol. 2004;11(2):103–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002;11(4):208–14.Google Scholar
  16. 16.
    Dropinski J, Szczeklik W, Rubis P, Sydor WJ. Anti-phospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction. Med Sci Monit. 2003;9(4):BR105–9.Google Scholar
  17. 17.
    Margarita A, Batuca J, Scenna G, Alves JD, Lopez L, Iannaccone L, Matsuura E, Ames PR. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci. 2007;1108:475–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114(5–6):593–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Plazak W, Pasowicz M, Kostkiewicz M, Podolec J, Tomkiewicz-Pajak L, Musial J, Podolec P. Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res. 2011;60(10):973–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, Hulley SB, Jacobs DR, Jr., Liu K, Manolio TA, et al. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials. 1991;12(1 Suppl):1S–77S.Google Scholar
  22. 22.
    Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol. 1998;25(4):675–80.Google Scholar
  23. 23.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedCrossRefGoogle Scholar
  24. 24.
    Budoff MJ, McClelland RL, Nasir K, Greenland P, Kronmal RA, Kondos GT, Shea S, Lima JA, Blumenthal RS. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2009;158(4):554–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee CD, Jacobs DR Jr, Hankinson A, Iribarren C, Sidney S. Cardiorespiratory fitness and coronary artery calcification in young adults: The CARDIA Study. Atherosclerosis. 2009;203(1):263–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Loria CM, Liu K, Lewis CE, Hulley SB, Sidney S, Schreiner PJ, Williams OD, Bild DE, Detrano R. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol. 2007;49(20):2013–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Okwuosa TM, Greenland P, Ning H, Liu K, Lloyd-Jones DM. Yield of screening for coronary artery calcium in early middle-age adults based on the 10-year Framingham Risk Score: the CARDIA study. JACC Cardiovasc Imaging. 2012;5(9):923–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Pletcher MJ, Hulley BJ, Houston T, Kiefe CI, Benowitz N, Sidney S. Menthol cigarettes, smoking cessation, atherosclerosis, and pulmonary function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arch Intern Med. 2006;166(17):1915–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Wilkins JT, Gidding S, Liu K, Ning H, Polak JF, Lloyd-Jones DM. Associations between a parental history of premature cardiovascular disease and coronary artery calcium and carotid intima-media thickness: the Coronary Artery Risk Development In Young Adults (CARDIA) study. Eur J Prev Cardiol. 2012. doi:10.1177/2047487312462801.
  30. 30.
    Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, Liang MH. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol. 1995;5(4):297–302.PubMedCrossRefGoogle Scholar
  31. 31.
    Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, Shoenfeld Y. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus. 2007;16(4):259–64.Google Scholar
  32. 32.
    Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford). 2003;42(5):645–51.CrossRefGoogle Scholar
  33. 33.
    Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54(12):3918–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924–9.CrossRefGoogle Scholar
  36. 36.
    Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, Shoenfeld Y, Wilson W, Roubey R. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12(7):499–503.PubMedCrossRefGoogle Scholar
  37. 37.
    Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum. 2003;48(10):2701–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Darcy S. Majka
    • 1
    • 2
  • Kiang Liu
    • 2
  • Richard M. Pope
    • 1
  • Elizabeth W. Karlson
    • 3
  • Thanh-Huyen T. Vu
    • 2
  • Marius Teodorescu
    • 4
    • 5
  • Rowland W. Chang
    • 2
  1. 1.Division of RheumatologyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of Preventive MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Section of Clinical Sciences, Division of Rheumatology, Immunology and AllergyBrigham and Women’s HospitalBostonUSA
  4. 4.TheraTest LaboratoriesLombardUSA
  5. 5.Section of RheumatologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations